Sandra Perez Baos
Associate at 2048 Ventures
New York, New York
Overview
Work Experience
Associate
2024 - Current
Analyst
2023 - 2024
2048 Ventures is a thesis-driven, earliest-stage venture capital firm. We are high-conviction, first-check lead investors backing founders building businesses differentiated through data and technology. We invest across North America and the UK. We focus on Biotechnology, Digital Health, AI/ML, Robotics, AR/VR, IoT, Hardware, Climate, Energy, Space, Mobility, Logistics, Security, Developer Tools and other Frontier Tech.
2048 Ventures is a thesis-driven venture capital firm.
Consultant
2023 - 2023
Advised the founding team on identifying and prioritizing the initial go-to-market indication for an mRNA binding protein therapeutic designed to rebuild muscle.
Postdoctoral Scientist
2019 - 2023
Immunology | T cells | mRNA translation • Led foundational research on T cell reprogramming in cancer and autoimmunity. • Secured NIH R01 and other funding that built upon my prior research. • Led and co-led three research projects ensuring timely, cost-effective execution. • Ran team meetings, communicated progress, and coordinated project updates. • Managed a colony of 200+ transgenic mice and conducted in vivo studies. • Presented at three conferences and published three peer-reviewed articles.
Director of Mentor Relations • Tech Sourcing Lead
2021 - 2023
Nucleate is a trainee-run program that supports the creation of life science startups by connecting PhD, MD, and MBA students with biotech executives, venture capitalists, and entrepreneurs. I was a founding member of the New York chapter. • Evaluated academic innovations for fit and feasibility in the Nucleate Activator program. • Built relationships with program advisors (academics, founders, investors, and executives). • Led mentor-mentee matching to ensure effective pairings across the program.
Business Development
2022 - 2023
• Reviewed invention disclosures and patent applications to assess their commercialization potential. • Prepared non-confidential technology summaries for stakeholder outreach. • Identified and engaged prospective industry partners (pharmaceutical, biotech, VCs). • Maintained a comprehensive pipeline of outreach efforts and outcomes, adding 100+ new contacts. • Participated in business meetings stemming from marketing efforts.
Laboratory Manager • Research Scientist
2018 - 2019
• Collaborated on multidisciplinary projects. • Contributed to resource allocation efforts and helped maintain efficient lab operations. • Supervised and mentored five junior team members. • Served as liaison among scientists, physicians, and management. • Declined a permanent position to pursue a postdoctoral opportunity in the U.S.
Ph.D. Candidate (PFIS Fellowship, ISCIII)
2013 - 2018
Rheumatoid Arthritis | Immunometabolism | Sarcopenia My Ph.D. thesis explored the role of the JAK/STAT pathway in rheumatoid arthritis, focusing on the link between lipid metabolism, inflammation, and sarcopenia.
Visiting Ph.D. Fellow (M-AES Fellowship, ISCIII)
2018 - 2018
I was awarded a competitive fellowship from the Carlos III Health Institute (ISCIII) to join the laboratory of Dr. Ikewaki (Division of Anti-Aging and Vascular Medicine), where I investigated the effects of JAK/STAT inhibition on reverse cholesterol transport in a rheumatoid arthritis mouse model.
Undergraduate Research, Immuno-oncology (M.Sc. Thesis)
2011 - 2012
I worked on a nanoparticle-based system of CX3CL1 delivery for cancer immunotherapy in the laboratory of Dr. Domingo F. Barber.
Undergraduate Research, CNS (JAE-intro Fellowship, CSIC)
2010 - 2010
I was a awarded a competitive fellowship by the Spanish National Research Council (CSIC) to join the laboratory of Dr. Coral Sanfeliu Pujol, where I explored the modulation of sirtuin-1 as a preventive therapy against age-associated neurodegeneration and Alzheimer's disease.
Undergraduate Research, Oncology (JAE-intro Fellowship, CSIC)
2009 - 2009
I was a awarded a competitive fellowship by the Spanish National Research Council (CSIC) to join the laboratory of Dr. Atanasio Pandiella, where I assessed in vitro the effects of the PI3K/mTOR inhibitor BEZ235 on ovarian carcinoma.